Fig. 13: Anti-tumor effect and safety evaluation of the co-delivery system in HT-1080 tumor-bearing mice. The doses of siRNA and PTX were 1 mg/kg and 5 mg/kg, respectively. | NPG Asia Materials

Fig. 13: Anti-tumor effect and safety evaluation of the co-delivery system in HT-1080 tumor-bearing mice. The doses of siRNA and PTX were 1 mg/kg and 5 mg/kg, respectively.

From: Amphiphilic dendrimer engineered nanocarrier systems for co-delivery of siRNA and paclitaxel to matrix metalloproteinase-rich tumors for synergistic therapy

Fig. 13

a Tumor growth curve. The black arrow denotes the time of drug administration. b The ratio of isolated tumor weight to body weight on the 10th day after drug administration. c Representative immunofluorescence images of tumor tissues stained with CD31 antibody. CD31 and cell nuclei were stained in green and blue, respectively, and red denotes the fluorescence of DiD, which indicates the nanocarriers. d The body weight variation in BALB/c nude mice after intravenous treatment. e Organ weight of different treatment groups. f Blood test of mice on the 14th day after the drug administration. Hematological indicators of WBC, RBC, PLT, HGB and GRN% counts are shown from 4 mice. All data are presented as the mean ± SD (n = 6, except for the hematological indicators). *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page